Connect with us

Media OutReach

The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist

Published

on

GUANGDONG, CHINA AND BAGSVÆRD, DENMARK – Media OutReach Newswire – 24 March 2025 – The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (Novo Nordisk) today announced that Novo Nordisk and TUL’s wholly-owned subsidiary The United Bio-Technology (Hengqin) Co., Ltd. (United Biotechnology), have entered into an exclusive license agreement for UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon in early-stage clinical development for the treatment of obesity, type 2 diabetes, and other diseases.

Under the license agreement, Novo Nordisk will obtain exclusive worldwide rights (excluding Chinese mainland, Hong Kong, Macau, and Taiwan) to develop, manufacture, and commercialize UBT251. United Biotechnology will retain the rights for UBT251 in Chinese mainland, Hong Kong, Macau, and Taiwan. United Biotechnology is eligible to receive an upfront payment of 200 million US dollars and potential milestone payments of up to 1.8 billion dollars from Novo Nordisk, as well as tiered royalties on net sales outside of Chinese mainland, Hong Kong, Macau, and Taiwan.

“Novo Nordisk is dedicated to providing improved treatment options for people living with obesity, type 2 diabetes, and other cardiometabolic diseases. The addition of a candidate targeting glucagon, as well as GLP-1 and GIP, will add important optionality to our clinical pipeline, as we look to develop a broad portfolio of differentiated treatment options that cater to the diverse needs of people living with these highly prevalent diseases,” said Martin Holst Lange, executive vice president for Development at Novo Nordisk. “We look forward to building on United Biotechnology’s scientific work and further exploring the potential best-in-class properties of UBT251 across cardiometabolic disease indications.”

United Biotechnology recently completed a randomized, double-blind, placebo-controlled phase 1b trial in China designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple subcutaneous injections of UBT251 in people with overweight or obesity.

A total of 36 patients were enrolled in three different dose groups (1mg, 1mg/3mg, 1mg/3mg/6mg). Each group adopted a dose titration method, with subcutaneous injection once a week for 12 consecutive weeks.

The safety profile of UBT251 was consistent with incretin-based therapies. The most common adverse events were gastrointestinal and the vast majority were mild to moderate in severity. In the highest dose group, the average weight of the people who completed the trial decreased by 15.1% from baseline, while the average weight of people in the placebo group increased by 1.5% from baseline.

“We are pleased to announce our exclusive license agreement with Novo Nordisk for UBT251. As a leading global biopharmaceutical company, Novo Nordisk holds a strong position in the treatment of chronic diseases,” said Mr. Tsoi Hoi Shan, the Chairman of TUL. “TUL is committed to strengthening its presence in the treatment of chronic diseases, including endocrine and metabolic disorders, while actively expanding its footprint in global markets. We believe that Novo Nordisk’s expertise will play a key role in accelerating the global development of UBT251.”

This collaboration represents a pivotal milestone in TUL’s ongoing efforts to establish a global strategic presence and demonstrates its commitment to innovation-driven transformation. TUL will continue to foster scientific innovation, advance high-quality and sustainable development, and accelerate the establishment of a globally competitive framework for manufacturing, R&D, and commercialization.

The closing of this transaction is subject to applicable regulatory clearance and other customary closing conditions.
Hashtag: #TUL

The issuer is solely responsible for the content of this announcement.

About UBT251

UBT251 is a long-acting synthetic peptide triple agonist targeting the receptors for GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and glucagon. It has demonstrated potent activity on all three receptors in a preclinical setting.

UBT251 is categorized as a Class 1 innovative drug in China, being developed by United Biotechnology for multiple indications. To date, UBT251 has been approved for clinical trials in China in adult type 2 diabetes, overweight or obesity, metabolic dysfunction-associated fatty liver disease (MAFLD), and chronic kidney disease (CKD), and for clinical trials in the United States in adult type 2 diabetes, overweight or obesity, and CKD.

United Biotechnology recently initiated a phase 2 trial for UBT251 in people with overweight or obesity in China.

About TUL and United Biotechnology

Founded in 1990, TUL (HKEX: 3933) is mainly engaged in the research and development, production and sales of pharmaceuticals, and ranks among the leading integrated pharmaceutical companies in China. TUL currently boasts seven production bases, covering intermediate products, bulk medicine , finished products, veterinary drugs, empty capsule casings, and medical devices, with the sales networks dotted across nearly 80 countries and regions. United Biotechnology, located in the Guangdong-Macao In-Depth Cooperation Zone in Hengqin, serves as the biopharmaceutical R&D headquarter of TUL. United Biotechnology focuses on the development of high-end biopharmaceuticals to treat major chronic diseases. For more information, please visit .

About Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 76,300 people in 80 countries and markets its products in around 170 countries. For more information, visit , , , and .

Advertisement

Media OutReach

From Wardrobe Staple to 10-Year Icon: XIXILI’s Seamless Panties Get a Colour Update

Published

on

SINGAPORE – Media OutReach Newswire – 7 March 2026 – Ten years on, XIXILI’s bestselling seamless panties remain a wardrobe essential for women who value simple, reliable comfort. The intimates brand, celebrated for thoughtful design and everyday ease, now introduces fresh new colours to the beloved range. Designed for invisible wear and lasting comfort, this signature style continues to earn the loyalty of those who prefer reliability over passing trends.

The Secret to a Decade of Loyalty

A decade of consistent customer trust speaks for itself. XIXILI’s seamless panties have earned a loyal following of women who return to the same style, year after year.

Whether it’s a breathable cotton panty for everyday basics or a sleek seamless style for fitted outfits, comfort remains the priority. The appeal comes down to the essentials: no visible panty lines, no adjusting throughout the day, and lightweight comfort that holds up from morning to night. For women juggling busy schedules, that kind of reliability makes all the difference.

“Our customers tell us these are the panties they don’t have to think about,” says Tara Tan, spokesperson for XIXILI. “They just work. That’s why women keep coming back.”

Designed for Every Body, Built to Last

The Full Coverage Mid-Rise Knitted Boyleg Panty delivers moderate coverage with a relaxed fit, suited for those who want fuss-free comfort. The High-Waist Knitted Boyleg Panty sits higher on the waist with gentle tummy smoothing, a go-to for wearing beneath tailored pieces and fitted silhouettes.

The Lightweight Seamless Microfiber Panty remains the star of the range. Its soft microfiber construction sits flat against the skin, creating an invisible finish under any outfit. A bestseller for ten consecutive years, this fan-favourite now comes in new colours, giving loyal fans a reason to refresh their collection.

The Foundation of Every Outfit

What sits beneath an outfit often sets the tone for the entire day. It’s the layer no one sees but everyone feels, allowing women to move through their routines with confidence, whether at work, running errands, or out with friends.

XIXILI’s decade-long bestseller continues to deliver on that promise. With new colours now available, updating the essentials is as effortless as the panties themselves.

To discover the full panties collection, visit XIXILI’s website to shop online with delivery to Singapore, or find your nearest XIXILI boutique across Malaysia.

Hashtag: #XIXILI #SGLingerie





The issuer is solely responsible for the content of this announcement.

About XIXILI

A proudly Malaysian brand, XIXILI offers fashion lingerie and shapewear that combines elegance with all-day comfort. With one of the most inclusive sizing ranges between A to I cups and 65 to 110cm band sizes, XIXILI designs for every body type. The brand is known for its expert fitters, premium materials, and dedication to helping women feel confident and supported.

XIXILI is also the first Malaysian lingerie brand to launch a 3D Avatar Try-On Tool, enabling women to virtually try on lingerie tailored to their unique body type and measurements. From everyday basics to occasion-ready pieces, XIXILI celebrates the beauty of real bodies, every day.

Continue Reading

Media OutReach

Huawei, Meralco, and SANXING Ningbo Launch Intelligent Distribution Solution and Lighthouse Initiative

Published

on

BARCELONA, SPAIN – Media OutReach Newswire – 6 March 2026 – During MWC2026, Huawei hosted a forum themed “Advancing All Intelligence, Empowering the Future Power System.” Together with Meralco (Philippines) and SANXING Ningbo, Huawei launched the Intelligent Distribution Solution (IDS) and announced a joint lighthouse initiative to advance power system development.

From left: Simon Zhou (General Manager of Overseas Marketing, SANXING Ningbo), David Sun (CEO, Huawei Electric Power Digitalization BU), Roque D. Bacani (Chief Information Officer, Meralco), and Perry Yang (Vice President, Huawei Optical Business Product Line) launching Huawei IDS

Communication, digitalization, and AI: Emerging cornerstones of future power systems that will accelerate the intelligent evolution of distribution networks

David Sun, CEO of Huawei’s Electric Power Digitalization BU, highlighted four drivers for energy transition: green energy and diversity, resilient grids, transparent distribution, and load electrification. He called for policy changes toward dispatch-market coordination. He also emphasized that communication, digitalization, and AI are becoming core production systems, requiring stronger capabilities in digital transformation, cybersecurity, and sustainable development.

At the forum, Mr. Sun unveiled the White Paper on Communication Target Networks for the Future Power System, introducing a pioneering architecture that features an intelligent and robust main network, integrated medium-voltage and transparent low-voltage networks, high-speed secure connectivity, and space-ground integration. The paper also outlines key tech trends, from optical and wireless to carrier and satellite communications, and underscores their transformative value.

Huawei highlighted its focus on intelligence and digitalization, working with industry players to drive power transformation. Global industry leaders also shared their insights: Al’Louise van Deventer (Technology and Engineering General Manager, Eskom) on future-ready digital practices; Momar Awa Sall (Transmission Grid Director, Senelec) on private wireless networks accelerating power modernization; Deniz COSKUN (Deputy General Manager, TEİAŞ) on restructuring communication networks for grid resilience; and Andy Liu (Overseas Solutions and Marketing Director, SANXING Ningbo) on the application of Huawei IDS.

Global industry leaders and partners join to explore the future of power systems

Power distribution networks are evolving from mechanized to automated and intelligent systems, driving technological and business model innovation. Despite creating new challenges for O&M, they have unlocked further opportunities for improving grid reliability and resource allocation.

At the forum, Huawei, Meralco, and SANXING Ningbo, unveiled the IDS that delivers four core capabilities—reliable communication, edge computing, cloud-edge collaboration, and low-voltage transparency—based on a cloud-pipe-edge-pipe-device architecture. It enables an intelligent low-voltage (400 V) distribution network with controllable line loss, visualized distribution rooms, and manageable renewables, transforming fragmented digital silos into open, integrated digital systems. The three companies also announced a lighthouse showcase initiative, sharing replicable and scalable digital transformation best practices.

Advancing digital and intelligent integration for a greener, more reliable grid

Communication, digitalization, and AI are at the heart of future power systems. Huawei will deepen R&D in digital, intelligent technologies, integrating advanced intelligence into power production. Together with global partners, Huawei is committed to developing with the power industry toward greater reliability, stronger security, and a low-carbon future.
Hashtag: #Huawei

The issuer is solely responsible for the content of this announcement.

Continue Reading

Media OutReach

Thailand Unveils Public–Private Alliance to Lead Asia’s Wellness Economy Revolution BDMS Wellness Clinic Rises as National Orchestrator of a Science-Powered, Luxury-Integrated Wellness Ecosystem

Published

on

BANGKOK, THAILAND – Media OutReach Newswire – 6 March 2026 – BDMS Wellness Clinic, the preventive healthcare center under Bangkok Dusit Medical Services Public Company Limited (BDMS), is spearheading a defining new chapter in Thailand’s national development strategy through strategic partnerships with public and private sectors both locally and internationally — including collaboration with the Global Wellness Institute (GWI), the preeminent global research and advisory organization dedicated to advancing the wellness economy, widely recognized for its data-driven industry intelligence, economic impact reports, and policy guidance shaping wellness markets worldwide. Together with global biotechnology pioneers including Illumina, Abbott, Straumann Group, and Gene Solutions, and further strengthened by distinguished GCC partners such as Neem Hospital and the MODAWI Platform, BDMS Wellness Clinic is forging a powerful bridge between Southeast Asia and the Middle East. Complemented by leading Thai institutions including National Healthcare Systems (N Health), Tourism Authority of Thailand (TAT), and Thailand Convention and Exhibition Bureau (TCEB), this alliance reflects an unprecedented convergence of science, policy, infrastructure, and international collaboration — reinforcing Thailand’s rise as Asia’s premier Wellness Economy hub.

Tanupol Virunhagarun, M.D., Chief Executive Officer of BDMS Wellness Clinic and BDMS Wellness Resort, Bangkok Dusit Medical Services Public Company Limited

A Multi-Sector Coalition at Unprecedented Scale

Led and orchestrated by BDMS Wellness Clinic, this alliance represents one of the most holistic cross-industry coalitions in Thailand’s health and tourism landscape. As the central integrator, BDMS Wellness Clinic unites public agencies, aviation leaders, hospitality icons, financial institutions, and global biotechnology innovators into a single, strategically aligned Wellness Ecosystem. Key national partners include the Thailand Convention and Exhibition Bureau (TCEB), Thailand Privilege Card Co., Ltd., and the Thai Spa Association, with regional connectivity strengthened by Bangkok Airways. The luxury and lifestyle dimension features Sri panwa Phuket, CELES SAMUI, Mövenpick BDMS Wellness Resort Bangkok, Dusit Thani Bangkok, King Power Corporation, Siam Piwat Co., Ltd., and Lancôme by L’Oréal Thailand.

Healthcare infrastructure and precision diagnostics are reinforced by National Healthcare Systems (N Health), enabling advanced laboratory networks, cross-border clinical data integration, and continuity of care. This capability is further elevated through collaboration with global medical and biotechnology leaders — Straumann Group in advanced dental innovation, Illumina in genomic sequencing, Abbott in precision diagnostics, and Gene Solutions in next-generation molecular testing.

Through this convergence of genomics, biomarker analytics, regenerative technology, and preventive medicine, BDMS Wellness Clinic delivers data-driven health optimization—from early disease detection and biological age assessment to personalized longevity programs. Together, under BDMS Wellness Clinic’s leadership, these partners form a fully integrated, science-powered ecosystem that transforms preventive care into measurable outcomes—firmly positioning Thailand at the forefront of Asia’s Wellness Economy.

From Healthcare Provider to National Orchestrator

BDMS Wellness Clinic has evolved beyond the traditional role of a healthcare provider to become the strategic integrator of Thailand’s Wellness Ecosystem—serving as the “National Orchestrator” uniting public institutions, private enterprises, academia, and global partners under one coordinated vision. Its mission extends far beyond treatment: to optimize healthspan, precise longevity science, and build a sustainable ecosystem where wellness becomes both a national economic engine and a form of diplomatic soft power. By synchronizing infrastructure, policy, aviation, hospitality, finance, and biotechnology, BDMS Wellness Clinic is repositioning Thailand from a destination known primarily for leisure and elective care into a global epicenter of evidence-based preventive medicine and measurable health optimization.

BDMS Wellness Clinic with Wellness Literacy: The Foundation of Sustainable Global Leadership

Sustainable global leadership demands more than world-class facilities—it requires a new generation of visionaries, scientists, and industry leaders equipped to redefine the future of health. BDMS Wellness Clinic has therefore launched a transformative Wellness Literacy strategy designed to cultivate world-class human capital, elevate professional standards, and shape a knowledge-driven ecosystem that positions Thailand at the forefront of preventive medicine and longevity science in Asia and beyond.

Through strategic alliances with leading institutions—including Thammasat University and King Mongkut’s Institute of Technology Ladkrabang (KMITL) in Thailand, as well as the University of Sharjah (UAE) and Singapore Management University (SMU)—BDMS Wellness Clinic is co-developing advanced curricula in preventive medicine, longevity science, and wellness management. These collaborations are establishing a new Asian benchmark for preventive healthcare education while producing a future-ready workforce for the global wellness economy. Beyond academia, BDMS Wellness Clinic is empowering entrepreneurs and industry operators nationwide, equipping hospitality, spa, and lifestyle businesses with measurable wellness standards—elevating Thailand’s entire value chain to international levels of excellence.

From Thailand to the World: BDMS Wellness Clinic’s Global Wellness Network

Extending its ecosystem beyond national borders, BDMS Wellness Clinic has forged strategic alliances with Neem Hospital—a leading private healthcare institution in the Sultanate of Oman known for its integrated clinical services and patient-centered care—and the MODAWI Platform, a digital health coordination platform that streamlines medical referrals, clinical data exchange, and cross-border care navigation.

Together, these partnerships establish a seamless referral and clinical integration network linking the GCC region with BDMS Wellness Clinic services. By combining hospital-based clinical excellence with digital health infrastructure, the model ensures continuity of care across borders—enabling patients to transition smoothly from initial consultation in the Middle East to advanced diagnostics, genomics, and longevity programs.

The Proof of Concept: “The Journey Within”

The flagship initiative, “The Journey Within,” translates vision into execution—serving as the living blueprint of the Wellness Ecosystem envisioned by BDMS Wellness Clinic. Anchored in three seamlessly integrated pillars—Travel, Stay, and Scientific Wellness—the concept redefines how a nation can deliver holistic, outcome-driven health experiences.

  • Travel: Luxury aviation partnerships, streamlined entry facilitation, and curated collaborations with lifestyle partners—ensuring effortless arrival and a seamless transition into an elevated wellness journey.
  • Stay: Curated luxury hospitality designed to immerse guests in restorative comfort and elevated living.
  • Scientific Wellness: Technological diagnostics, genomics, and precision-driven longevity programs delivering measurable health transformation.

For more information about The Journey Within, click https://bdmswellness.co/40LNk4v

Hashtag: #BDMSWellnessClinic #สุขภาพที่ดีเริ่มที่การป้องกัน #LiveLongerHealthierHappier #PreventiveMedicine #LifestyleMedicine #ScientificWellness #WellnessHubThailand




The issuer is solely responsible for the content of this announcement.

BDMS Wellness Clinic

BDMS Wellness Clinic, a pivotal entity within the Bangkok Dusit Medical Services (BDMS) network—Thailand’s leading operator of private hospitals—embodies a forward-thinking approach to healthcare, prioritizing prevention over cure. Specializing in early detection and prevention of diseases, our clinic offers a holistic suite of services, including advanced dental care and fertility treatments. Leveraging cutting-edge science and technology, BDMS Wellness Clinic not only anticipates future health challenges but also enhances the quality of life, marking its stature as Asia’s premier healthcare facility dedicated to elevating both mental and physical well-being.

For more details:

Facebook: Facebook.com/BDMSWellnessClinic
Instagram: @BDMSWellness

Media Inquiries: Media Inquiries: Please contact Marketing and Communication Department, BDMS Wellness Clinic Co. Ltd.

Chanokphat Pawangkanan 098-369-5963 Email: ch***********@**********ss.com

Sasiwimol Techawanto 092-807-5893 Email:

Continue Reading

Trending